JLM-BioCity & BioMed-MBA invites you to:

“Building the China-Israel Biomedical Alibaba: Bringing Great Israeli Medical Technology to the Chinese Market”
with Special Guest – Huang Qingxi, Chair, ICB

Sunday, April 14, 2019, Hebrew University at Mt. Scopus campus – room 2102, 2d floor, in the School of Business Administration, the Faculty of Social Sciences (Social Science Gate, Gate 1).

For FREE PARKING, please fill out the form:

Huang Qinqxi will be presenting his vision on investing in Israeli Biomed and E-health start-ups by clusters to rapidly enter the markets in China. For the last 23 years, Huang has established a platform for funding promising Chinese Biomed companies to bring them rapidly into the Chinese market. In 2017, Huang became the controlling shareholder of the Israeli public traded ICB Biotechnology Investments Ltd and converted it into a leading Israeli investment platform for Biomed and e-health health companies.

ICB ‘s unique know-how and networking in China coupled with its understanding of Chinese market trends enable it to identify unique business and financial opportunities and facilitate fruitful matches. The unique business model developed by combined Israeli-Chinese professional experts provides Israeli companies, unlike other models, the ability to maintain their IP and assets. ICB’s current focus is in wound healing, cardiovascular diseases, and any related segments, and shall be expanded into other clusters. To date, 6 successful Israeli companies have been invested in. Huang believes in creating profound and beneficial partnerships for both sides which is the only way to create a long term successful investment strategy.

18:00 Registrations and Networking
18:30 Greetings
Opening – Yaron Suissa, CEO, JLM-BioCity
– Lior Shaltiel, BioMedMBA, School of Business Administration, HUJI
– Prof Haim Lotan, Director of The Heart Institute & Head of the Cardiovascular Division, Hadassah Medical Center & Director, ICI2019 “The Cardiovascular Startup Scene in Israel”
– Doron Ben-Ami, CEO, ShizimXL “The new ICB- ShizimXL Medtech Accelerator”
– Pitches from promising Bio Companies:
* Jeff Gabay, Argaman Technologies
* Ofir Aharon, Scade Medical
* Ofer Spottheim, Super Plaster
* Ofer Harpak, Oxitone
* Modi Teicher, Bloomsbury

19:00 Huang Qingxi, Chair, ICB
“Building the China-Israel Biomedical Alibaba: Bringing Great Israeli Medical Technology to the Chinese Market”
19:20 – 19:30 Questions & Answers
19:30 – 20:00 Networking

About Mr. Huang Qingxi

Starting 23 years ago, Mr. Huang Qingxi has held major positions in various holding companies. He brought back a nearly bankrupt company to the capital market and was responsible for a 15-fold stock price increase and a 26 billion CNY increase in market value. In 2005, he won the “1st Top Ten Charity Enterprise Award” in the Hunan Province, China.
Huang is president of Central Bio-MD Valley Technology Co. Ltd and serving as a director in several Hong Kong-listed companies.
Recently he appeared in Globes https://en.globes.co.il/en/article-china-plus-israel-equals-america-1001247127

About ICB Biotechnology Investments Ltd (previously named BSP)
ICB is an Israeli company that has been in the biotech industry for many years. In 2017, Mr. Huang Qingxi, a Chinese investor, took over its control, shifting its priority to become an investment company in the biomedical field, creating a leading high-tech healthcare platform in Israeli medical companies. ICB directly provides equity funding to bring Israeli companies into China, the world’s biggest emerging market. Backed by prominent partners in China, ICB is a public company traded under the ICB symbol since March 2018 on the Tel Aviv Stock Exchange.